Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease

NCT03856853 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)

Interventions

DRUG: Pirfenidone
OTHER: placebo

Sponsor

Beijing Continent Pharmaceutical Co, Ltd.

Collaborators

[object Object]
[object Object]